Alzheimer's: The Latest Assessment and Treatment Strategies
, by Grossberg, George T., M.D.- ISBN: 9780763765798 | 0763765791
- Cover: Paperback
- Copyright: 11/1/2009
General Information About Alzheimer's Disease | p. 1 |
What Is Alzheimer's Disease? | p. 2 |
How Does Alzheimer's Disease Affect PatientsĘ Lives? | p. 3 |
Stages of Alzheimer's Disease | p. 3 |
How Common Is Alzheimer's Disease? | p. 5 |
What Are the Risk Factors and Potential Protective Factors in Alzheimer's Disease? | p. 6 |
Risk Factors | p. 6 |
Protective Factors | p. 8 |
Chapter Summary | p. 10 |
Diagnosing and Assessing Alzheimer's Disease | p. 11 |
What Are the Typical Presenting Features in Patients With Alzheimer's Disease? | p. 11 |
Cognition | p. 12 |
Activities of Daily Living | p. 13 |
Behavior | p. 13 |
What Are the Criteria for Diagnosing Alzheimer's Disease? | p. 14 |
What Tools Are Available for Clinical Assessment of Alzheimer's Disease? | p. 18 |
Clinical Interview (Medical and Psychiatric History) | p. 18 |
Laboratory Evaluations | p. 22 |
Radiological Findings | p. 22 |
Genetic Testing | p. 23 |
Neuropsychological Testing | p. 23 |
Diagnostic Workup Summary | p. 27 |
What Differentiates Alzheimer's Disease From Normal Aging and From Other Disorders? | p. 27 |
Normal Aging | p. 27 |
Subjective Cognitive Impairment | p. 27 |
Age-Associated Memory Impairment | p. 29 |
Mild Cognitive Impairment | p. 29 |
Vascular Dementia | p. 29 |
Lewy Body Dementia (LBD) | p. 30 |
Parkinson Disease Dementia (PDD) | p. 30 |
Mixed Dementia | p. 30 |
Frontotemporal Dementia | p. 31 |
Geriatric Depression | p. 31 |
Chapter Summary | p. 31 |
Pharmacotherapy in Alzheimer's Disease | p. 33 |
What are the Neuroanatomical and Neurochemical Hallmarks of Alzheimer's Disease? | p. 34 |
Biochemical Factors Related to Alzheimer's Disease | p. 34 |
Specific Brain Areas Involved in Alzheimer's Disease | p. 34 |
What Medications Are Available for Stabilization or Improvement of Symptoms in Patients With Alzheimer's Disease? | p. 35 |
Cholinesterase Inhibitors (ChEI) | p. 35 |
NMDA Receptor Antagonist: Memantine (Namenda) | p. 38 |
Treatment Recommendations for Patients With Alzheimer's Disease | p. 39 |
Efficacy of Treatment | p. 40 |
What Medications Are Used to Treat BPSD in Patients With Alzheimer's Disease, and What Are Their Efficacies? | p. 45 |
Atypical Antipsychotics | p. 45 |
Typical or Conventional Antipsychotics | p. 47 |
Antidepressant Medications | p. 48 |
Benzodiazepines | p. 48 |
Anticonvulsants | p. 48 |
Cholinesterase Inhibitors | p. 49 |
Memantine | p. 49 |
What Alternative Treatments Can Be Used to Treat Patients With Alzheimer's Disease? | p. 50 |
Estrogen | p. 50 |
Omega-3 Fatty Acids | p. 50 |
Vitamin C and Vitamin E | p. 51 |
Mediterranean Diet | p. 52 |
What Are the Emerging or Disease-Modifying Treatments for Patients With Alzheimer's Disease? | p. 52 |
Anti-Inflammatory Drugs | p. 53 |
Statins | p. 53 |
Amyloid-Modifying Agents | p. 53 |
Immune Therapies | p. 54 |
Neurogenesis Agents | p. 55 |
Methylene Blue | p. 56 |
How Does Comorbidity Affect Pharmacotherapy Choices for Alzheimer's Disease? | p. 56 |
Comorbid Conditions | p. 56 |
Cost of Caring for Alzheimer's Disease Patients With Comorbid Conditions | p. 57 |
How Can Alzheimer's Disease Be Prevented Through Lifestyle Modifications? | p. 58 |
Chapter Summary | p. 59 |
Psychosocial Treatments for Alzheimer's Disease | p. 61 |
What Psychosocial Interventions Are Used to Treat BPSD in Patients With Alzheimer's Disease, and How Effective Are They? | p. 61 |
Depression | p. 62 |
Anxiety | p. 63 |
Wandering | p. 64 |
Apathy | p. 65 |
Agitation | p. 66 |
Psychosis | p. 67 |
Sleep Abnormalities | p. 69 |
What Other Therapeutic Interventions Can Be Tried in Patients With Alzheimer's Disease? | p. 70 |
Reminiscence Therapy | p. 70 |
Validation Therapy | p. 70 |
Reality Orientation | p. 71 |
Chapter Summary | p. 71 |
Ethical, Legal, and Caregiver Issues in Alzheimer's Disease | p. 73 |
What Are the Important End-of-Life Issues in Alzheimer's Disease? | p. 73 |
When to Stop Treatments | p. 73 |
Feeding Issues in Patients With Alzheimer's Disease | p. 74 |
Hospice Care for Patients With Alzheimer's Disease | p. 74 |
What Are the Important Legal Issues Confronting Families of Patients With Alzheimer's Disease? | p. 75 |
Advance Directives | p. 75 |
Guardianship | p. 76 |
What Are the Important Issues for Caregivers of Patients With Alzheimer's Disease? | p. 78 |
Stress | p. 78 |
Role of Caregiver Education in Delaying Institutionalization | p. 79 |
Resources for Caregivers of Patients With Alzheimer's Disease | p. 80 |
What Are the Various Care Options for Patients With Alzheimer's Disease?80 | |
Adult Daycare Centers | p. 80 |
Assisted Living | p. 81 |
Nursing Homes | p. 82 |
Special Care Units | p. 83 |
Chapter Summary | p. 84 |
Appendix: Resources for Caregivers and Physicians | p. 85 |
Resources for Caregivers | p. 85 |
Internet Resources | p. 85 |
Books and Articles | p. 85 |
Internet Resources for Physicians | p. 86 |
Glossary | p. 87 |
References | p. 91 |
Index | p. 105 |
Table of Contents provided by Ingram. All Rights Reserved. |
The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.
Digital License
You are licensing a digital product for a set duration. Durations are set forth in the product description, with "Lifetime" typically meaning five (5) years of online access and permanent download to a supported device. All licenses are non-transferable.
More details can be found here.